drugset / Trial / NCT04400695
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ，previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.
Timeline
- Start
- 2020-09-29
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | — | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Vinorelbine | Small molecule | — | — |